Sera Prognostics, a Salt Lake City, Utah-based health diagnostics company focused on women and babies through individualized prenatal care, raised $36m in Series D financing.
The round was led by Blue Ox Healthcare Partners alongside two strategic healthcare companies and participation from existing investors Domain Associates, InterWest Partners, Laboratory Corporation of America Holdings, Catalyst Health Ventures, and Chione Ltd.
The company intends to use the funds to increase commercialization of its test and to measure real-world clinical improvements and economic savings in collaboration with top health plans and providers.
Led by Gregory C. Critchfield, MD, MS, Chairman and Chief Executive Officer, Sera Prognostics is advancing the PreTRM® test, a clinically-validated, commercially available biomarker blood test that accurately assesses a woman’s individualized risk of premature delivery.
The blood test provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies and measures and analyzes proteins in the blood that are highly predictive of preterm birth.